Intellia Therapeutics, a gene editing company, focuses on Crispr/Cas9-based therapeutics. Crispr/Cas9 technology is pivotal for precisely altering genomic DNA sequences to treat genetically defined diseases like ATTR amyloidosis and sickle cell disease. By utilizing in vivo and ex vivo therapies, Intellia aims to address diseases with high unmet medical needs. Collaborations with companies like Regeneron […]
Tag: Regeneron
Regeneron Acquires Hansoh’s GLP-1/GIP Agonist in $2bn Deal
Regeneron has secured the rights to Hansoh’s late-stage GLP-1/GIP receptor agonist [HS-20094] in a significant $2 billion deal. This acquisition enables Regeneron to explore synergistic combinations with its own drugs, aiming to tackle muscle loss and potential obesity-related comorbidities like cardiovascular diseases, diabetes, and liver conditions. Boaz Hirshberg, Regeneron’s senior vice president of clinical development […]
Regeneron’s Strategic Licensing for Dual GLP-1/GIP Receptor Agonist
Regeneron Pharmaceuticals, Inc. expands its clinical-stage obesity portfolio through a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited. This agreement grants Regeneron exclusive rights outside of China for HS-20094, a novel dual GLP-1/GIP receptor agonist. The In-Licensing Transaction involves potential benefits, regulatory considerations, and anticipated clinical development pathways. Regeneron aims to address obesity-related comorbidities […]
